PHARMA SIGNALOPEN RESEARCH PLATFORM →
CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

Global Trial in APG2575 for Patients With CLL/SLL

NCT06104566 · Phase 3 · Recruiting

PHASEPhase 3
STATUSRecruiting
ENROLLMENT400
EST. COMPLETION2026-12-31

Conditions

CLL/SLL

Interventions

lisaftoclax +BTK inhibitorBTK inhibitor

Study details

SPONSORAscentage Pharma Group Inc.
START DATE2023-12-20

Related company profiles

Ascentage Pharma

6855.HK

Primary source

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier
NCT06104566
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record